EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Nano-drug delivery systems for the treatment of brucellosis: current evidence, translational lessons from tuberculosis nanotherapy, and future directions

Jiazheng Tian, Xinle Li, Hui Tian, Shuxia Ao, Delihai Hu’he, Guoli Liu, Wanru Geng

Frontiers in Cellular and Infection Microbiology · 09.11.2026 · 16

DOI: 10.3389/fcimb.2026.1855690 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Cellular and Infection Microbiology, online erschienen am 09.11.2026. Verfasst von Jiazheng Tian und 6 weiteren Autor:innen. Die Arbeit nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Brucellosis, caused by facultative intracellular bacteria, evades host immunity and resists conventional antibiotics, frequently progressing to chronic infection and posing substantial clinical challenges.

Objective

This review aims to comprehensively summarize recent advances in nanocarrier-based drug delivery systems for the treatment of intracellular bacterial infections, using Brucella as a representative pathogen, and to explore their potential for future clinical application.

Methods

We systematically reviewed the design strategies, characteristics, and anti-Brucella efficacy of various nano-drug delivery systems loaded with antibiotics such as doxycycline and rifampicin. In addition, we evaluated combination therapy approaches, including stimulus-responsive drug release and photothermal therapy.

Results

Nanocarriers elevate intracellular drug deposition, extend therapeutic retention time and mitigate systemic side effects, thereby yielding markedly better antibacterial performance than unencapsulated antibiotics. Combined therapeutic regimens can further boost anti-Brucella potency.

Conclusion

Nano-drug delivery platforms hold great promise for the clinical management of intracellular pathogens exemplified by Brucella spp. Future research should prioritize long-term biosafety assessment, scalable manufacturing processes, and clinical translation.

Zitieren

APA

Tian, J., Li, X., Tian, H., Ao, S., Hu’he, D., Liu, G., & Geng, W. (2026). Nano-drug delivery systems for the treatment of brucellosis: current evidence, translational lessons from tuberculosis nanotherapy, and future directions. Frontiers in Cellular and Infection Microbiology, 16. https://doi.org/10.3389/fcimb.2026.1855690

Vancouver

Tian J, Li X, Tian H, Ao S, Hu’he D, Liu G, et al. Nano-drug delivery systems for the treatment of brucellosis: current evidence, translational lessons from tuberculosis nanotherapy, and future directions. Frontiers in Cellular and Infection Microbiology. 2026;16. doi:10.3389/fcimb.2026.1855690

BibTeX
@article{Tian2026,
  author = {Tian, Jiazheng and Li, Xinle and Tian, Hui and Ao, Shuxia and Hu’he, Delihai and Liu, Guoli and Geng, Wanru},
  title = {Nano-drug delivery systems for the treatment of brucellosis: current evidence, translational lessons from tuberculosis nanotherapy, and future directions},
  journal = {Frontiers in Cellular and Infection Microbiology},
  year = {2026},
  volume = {16},
  doi = {10.3389/fcimb.2026.1855690}
}
Kostenlos starten →